MT Newswires
RBC Lifts Price Target on Gilead Sciences to $103 From $100, Keeps Sector Perform Rating
📈
AI Sentiment
Highly Positive
8/10
Gilead Sciences Inc. News
Latest updates and market news for GILD
3 news
Jan 15 - Jan 21, 2026
Page 1
GlobeNewswire
Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales
📈
AI Sentiment
Highly Positive
8/10
Share this news page